A recent study engineered a TanCAR targeting both IL-13Rα2 and TGF-β, designed to reprogram tumor-specific T cells to convert TGF-β from an immunosuppressant to an immunostimulant. This evidence concerns the gene IL13RA2 and neoplasm.